New EUA Places Abiomed Firmly in the COVID-19 Conversation
Sometimes when the discussion of tackling the novel coronavirus comes up, the use of medical devices gets lost in the shuffle. Most of the conversation surrounding COVID-19 comes from either the promise of a vaccine or the expansion of tests.
Abiomed is adding to the conversation surrounding medtechâs potential contribution to the treatment of COVID-19 patients. Monday, the Danvers, MA-based company by receiving Emergency Use Authorization for a device to treat COVID-19 related right heart failure patients.
The Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure and initially won FDA approval in 2017.
âIn this case, FDA authorized emergency use of the Impella RP to unload the right ventricle of the heart and provide mechanical circulatory support, specifically for COVID-19 patients,â Shon Chakrabarti, MD of Abiomedâs Medical Office Team, told MD+DI. â[This] include[s] patients who have pulmonary embolism where a blood clot forms in the pulmonary artery or travels from another area of the body, causing the hemodynamic collapse of the right ventricle.â
Chakrabarti added, âwhat weâve learned with COVID-19 ⦠is that itâs not like a lot of the other respiratory viruses that have caused pandemics in the past. We definitely see a ...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular COVID-19 Source Type: news
More News: Cardiology | Cardiovascular | Coronavirus | COVID-19 | Education | Emergency Medicine | Environmental Health | Heart | Heart Failure | Hospitals | Medical Devices | Pandemics | Partnerships | Pulmonary Thromboembolism | Respiratory Medicine | Vaccines